Ocular Therapeut OCUL

$6.96 -0.33 (-4.53%)

Valuation

Market cap
1,528,527,000
Revenue TTM
$51,950,000
Net income TTM
$-265,940,000
PE ratio
0.00
Forward PE
—
Profit margin
-511.92%
Debt to equity
0.14

Trading

Volume
4,958,100
Avg volume
2,913,992
Day's range
$6.93 – $7.43
Shares out
219,616,000
Stochastic %K
1%
Beta
1.00
Analysts
Strong Sell
Price target
$26.73

Price

Company profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunc...

Show more

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 357 4000
Website
https://www.ocutx.com
Address
14 Crosby Drive, 3rd Floor, Bedford, United States

Latest news

Stocktwits

Harvo Oct 4, 3:47 PM
$OCUL The market is currently pricing Axpaxli as a niche indication with no credit towards DR. SOL-R NI and Superiority to HD will be instramentel in taking the markets view of a niche or base case to a 3-5 billion franchise with a 15-20 billion market cap. That or, real world evidence in the clinic as retinal physicians learn application of the therapy as it relates to patients. Either way, the market shows no indication of giving ocul any credit on anything that has not been proven conclusively in a real world matchup.
1 replies
Loparla Oct 4, 9:02 AM
$OCUL
0 replies
MaxKlim Oct 4, 8:15 AM
$OCUL Baird bullish on regulatory alignment, continue to see Axpaxli as a blockbuster, and are raising PT to $30. now modeling a US launch for Axpaxli in wet AMD in 2027 vs. 2028 previously and increasing our probability of success to 90% from 70% (our wet AMD US peak sales of ~$2.3B is unchanged)
0 replies
MaxKlim Oct 4, 6:51 AM
$OCUL $KOD Did Kodiak release something detailed like that? I need to lock in profits before the dilution and buy OCULAR.
0 replies
johnj2 Oct 3, 8:24 PM
$OCUL Euretina presentation: https://investors.ocutx.com/static-files/f9d9aeed-36e4-466d-bc65-f411547b38be
1 replies
ShortSuckieTuckie Oct 3, 5:53 PM
$OCUL This is what we need to win... The recommended dose for AXPAXLI is one 450 mg intravitreal insert administered approximately 4 weeks after two initial intravitreal injections of EYLEA (aflibercept) 2 mg or an approved biosimilar, administered 4 weeks apart; or 4 weeks after the last injection for a stable patient using Eylea HD or Vabysmo. Following administration of AXPAXLI, patients should undergo optical coherence tomography and visual acuity evaluations at 8 and 16 weeks to inform the need for supplemental treatment with EYLEA (aflibercept) 2 mg or an approved biosimilar. An additional AXPAXLI insert may be administered at Week 24 (+12/-0 weeks) based on visual and anatomic outcomes. And then potentially: Extended dosing intervals (one AXPAXLI insert once every 52 weeks, +0/- 12 weeks) may be considered after [X months/one year] of successful response based on visual and anatomic outcomes.
2 replies
Appulen Oct 3, 7:39 AM
$OCUL I strongly believe there are likely informal & confidential strategic discussions ongoing as we speak for Ocul. Everyone is waiting for the NDA submission to put things together for an offer. Pravin Dugel last Buyout timeline of Ivirec in 2023, as an example of his experience and how quickly things escalate: December 2022: NDA submission of new drug January 2023: Initial informal & confidential discussions of buyout with Astellasakes March 31, 2023: Astellasakes formal cash offer Mid-April 2023: Competitors like Bayer submitted alternative bids April 27, 2023: Astellas raised its buyout offer April 30, 2023: The companies officially announced agreement July 11, 2023: Astellas completed the acquisition. and Ivirec stock was delisted August 2023: FDA approval of new drug
1 replies
MaxKlim Oct 3, 7:23 AM
$OCUL Chances of Priority Review (6-month review instead of 10) Experts estimate a high probability (approximately 70–75%) that the FDA will grant the AXPAXLI application Priority Review status.
2 replies